All In Biotech

Drug Trial Radar · NCT06106841

TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

A Phase Ib/II Clinical Trial of TQB3909 Tablets in Subjects With Relapsed or Refractory MCL Safety and Efficacy

Last checked: Nov 19, 2026Latest source record: Dec 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

19

Actual

Start

Oct 5, 2023

Primary completion

Oct 16, 2024

Study completion Oct 16, 2024

Sponsor

Sponsor type
Industry
First posted
Oct 30, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study to assess the safety of TQB3909 monotherapy in participants with relapsed or refractory MCL.

Conditions

  • Mantle Cell Lymphoma

Interventions

  • 400mg of TQB3909 tabletsDrug

    TQB3909 tablets 400mg, TQB3909 tablets is a B-cell lymphoma (BCL)-2 inhibitor.

  • 600mg of TQB3909 tabletsDrug

    TQB3909 tablets 600mg, TQB3909 tablets is a B-cell lymphoma (BCL)-2 inhibitor.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recommended phase II dose (RP2D)Time frame: Baseline up to 48-weeks

Locations

28 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China

  • Chongqing University Hospital

    Chongqing, Chongqing Municipality, China

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China

  • Gansu Provincial Cancer Hospital

    Lanzhou, Gansu, China

  • Guangxi Medical University Cancer Hospital

    Nanning, Guangxi, China

  • The Affiliated Hospital of Chengde Medical College

    Chengde, Hebei, China

  • The Second Affiliated Hospital of Harbin Medical University

    Harbin, Heilongjiang, China

  • Affiliated Cancer Hospital of Harbin Medical University

    Harbin, Heilongjiang, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology

    Wuhan, Hubei, China

  • The Affiliated Hospital of Xuzhou Medical University

    Nanjing, Jiangsu, China

  • The Second Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China

  • The First Affiliated Hospital Of Soochow University

    Suzhou, Jiangsu, China

  • Jinzhou Central Hospital

    Wuxi, Jiangsu, China

  • Jilin Cancer Hospital

    Changchun, Jilin, China

  • The First Hospital of Jilin University

    Changchun, Jilin, China

  • The Second Hospital of Dalian Medical University

    Dalian, Liaoning, China

  • Binzhou Medical University Hospital

    Binzhou, Shandong, China

  • Linyi People's Hospital

    Linyi, Shandong, China

  • Shanghai Huashan Hospital

    Shanghai, Shanghai Municipality, China

  • Tongji hospital of Tongji University

    Shanghai, Shanghai Municipality, China

  • Heping Hospital Affiliated to Changzhi Medical College

    Changzhi, Shanxi, China

  • The Affiliated Hospital of Southwest Medical University

    Luzhou, Sichuan, China

  • Tianjin Medical University Cancer Institute and Hospital

    Tianjin, Tianjin Municipality, China

  • Institute of Dematology & Blood diseases Hospital

    Tianjin, Tianjin Municipality, China

  • Xinjiang Uygur Autonomous Region People's Hospital

    Ürümqi, Xinjiang, China

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

  • The First Affiliated Hospital of Ningbo University

    Ningbo, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.